Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE AND ETHINYL ESTRADIOL versus PREMPRO PREMPHASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE AND ETHINYL ESTRADIOL versus PREMPRO PREMPHASE.
DROSPIRENONE AND ETHINYL ESTRADIOL vs PREMPRO/PREMPHASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drospirenone is a spironolactone analogue with anti-mineralocorticoid and anti-androgenic activity. It suppresses gonadotropin secretion, inhibiting ovulation. Ethinyl estradiol provides negative feedback on LH and FSH, preventing follicular development and ovulation.
Prempro/Premphase contains conjugated estrogens (CE) and medroxyprogesterone acetate (MPA). Estrogens bind to estrogen receptors (ERα/ERβ), activating genomic and non-genomic signaling, promoting proliferation of estrogen-responsive tissues, and modulating lipid metabolism. MPA is a progestin that binds to progesterone receptors, antagonizing estrogen-induced endometrial hyperplasia and blunting estrogen effects on breast tissue. The combination suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.02 mg or 0.03 mg) orally once daily for 21 days followed by 7 days of placebo, or 24 active tablets followed by 4 placebo tablets depending on formulation.
Conjugated estrogens 0.625 mg/medroxyprogesterone acetate 2.5 mg (Prempro) or 0.625 mg/5 mg (Premphase) orally once daily.
None Documented
None Documented
Drospirenone: approximately 30-35 hours (terminal), allowing once-daily dosing. Ethinyl estradiol: approximately 13-20 hours (terminal), supporting daily administration.
Conjugated estrogens: 10-24 hours (terminal, prolonged in hepatic impairment). Medroxyprogesterone acetate: 12-17 hours (terminal).
Drospirenone: ~40-50% renal (as glucuronide conjugates), ~50-60% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, primarily as glucuronide and sulfate conjugates.
Renal (90-95% as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal (5-10%).
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination